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Abstract: Background: DNA mismatch repair (MMR) is a system for repairing errors in DNA
replication. Cancer cells with MMR deficiency can have immunohistochemical loss of MMR protein
expression leading to a hypermutable phenotype that may correlate with anti-PD1 efficacy. Scant data
exist about immunohistochemical loss of MMR protein expression in high-grade gliomas (HGG).
Materials and Methods: We performed a large multicenter retrospective study to investigate the
frequency and the prognostic role of immunohistochemical loss of MMR protein expression in HGG
patients; we nevertheless evaluated the association between this status and clinical or molecular
characteristics. Immunohistochemical loss of MMR protein expression was recorded as partial or
complete loss of at least 1 MMR protein. Results: We analyzed the expression of MMR proteins in
tumor tissue of 355 consecutive patients. Partial and complete immunohistochemical loss of MMR
proteins was found in 43/355 samples (12.1%) and among these, 15 cases (4.2%) showed a complete
loss of at the least one MMR protein. Alteration of MSH2 expression was found in 55.8%, MSH6 in
46.5%, PMS2 in 34.9%, and MLH1 in 30.2%. Alteration of MMR protein expression was statistically
more frequent in anaplastic gliomas, in recurrent disease, in patients treated with temozolomide,
and in IDH-mut gliomas. Immunohistochemical loss of MMR proteins was not associated with
survival, adjusting for clinically relevant confounders. Conclusions: MMR protein expression status
did not affect survival in HGG patients. We identified clinical and molecular characteristics correlating
with immunohistochemical loss of MMR proteins expression. A large study should be performed to
analyze its predictive role of immune checkpoint inhibitor efficacy in these subgroups of patients.
Keywords: high-grade glioma; mismatch repair; microsatellite instability; immunotherapy
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1. Introduction
High-grade gliomas (grade III and IV gliomas according to 2016 WHO CNS classification [1])
represent aggressive primary brain tumors in adults; although the progress of recent years has allowed
us to obtain more information about these diseases, from both a clinical and a molecular point of view,
treatment options remain limited and prognosis remains poor. DNA mismatch repair (MMR) is a system
to identify and repair mismatched nucleotides (erroneous insertion, deletion, and misincorporation)
in order to guarantee genomic stability and integrity. Essentially, the MMR system depends on four
key genes: mutS homologue 2 (MSH2), mutS homologue 6 (MSH6), mutL homologue 1 (MLH1),
and post-meiotic segregation increased 2 (PMS2). These main proteins of the MMR complex are usually
identified through immunohistochemical analysis in clinical settings. In the case of MMR proteins that
are not expressed, dysfunctional, or inactivated, it could induce an hypermutated profile in cancer cells
showing 10 to 100 times more somatic mutations than MMR-proficient cancers; this hypermutation state
could lead to the generation of neoantigens that can activate the immune system and promote antitumor
activity [2]. Indeed, Hodges et al. [3] demonstrated that immunohistochemical loss of at least one MMR
protein expression was associated with the hypermutation profile in glioma patients. This correlation
was confirmed in further recent studies [4–6]. Immune checkpoint inhibitors, in particular Nivolumab
and Pembrolizumab (anti PD-1), were tested in several types of tumors with MMR deficiency
(MMRd), showing impressive antitumor activity [7–12]; based on these results, the FDA approved
the use of pembrolizumab in patients with any solid tumor with MMRd after progression from
prior chemotherapy [13]. However, in HGG patients, immune checkpoint inhibitors demonstrated
poor efficacy: nivolumab failed to extend survival compared to standard treatment in two phase III
trials analyzing newly diagnosed MGMT (O6-Mthylguanine-DNA Methyltrasferase)-methylated and
recurrent glioblastoma patients [14]; moreover, pembrolizumab showed poor results in a phase Ib
trial compared to bevacizumab, in selected recurrent PD-L1 positive, glioblastoma patients [15]. In all
these studies, patient selection according to MMR status or TMB (Tumor Mutational Burden) was not
performed. Scant data are available on MMR complex proteins in high-grade gliomas [16], and deficit of
expression of MSH6 might contribute to alkylating agent resistance and recurrence [17,18]; despite that,
the role of MMRd in terms of survival in this setting of patients seems unclear. In order to improve
knowledge of MMR status in high-grade gliomas and in consideration of its possible predictive role
of immune checkpoint inhibitor efficacy, we performed a large multicenter study to investigate the
frequency and the type of immunohistochemical loss of MMR protein expression, its association with
clinical, histological, and molecular characteristics, and its correlation with survival in HGG patients.
2. Results
2.1. Patient Characteristics
Between April 2018 and May 2019, 355 consecutive high-grade glioma patients (median age
56 years; 241 males and 114 females) were enrolled. The study cohort included 315 (88.7%) grade IV
glioblastoma and 40 (11.3%) grade III glioma (30 anaplastic astrocytoma, 2 anaplastic ependymoma,
and 8 anaplastic oligodendroglioma). Patient characteristics (overall and stratified by grade III and
IV glioma) are reported in Table 1. Eastern Cooperative Group (ECOG) performance status (PS) at
diagnosis was ECOG 0-1 in 87.3% of patients and radical surgery was performed in 70.4% of cases.
Molecular analyses were done on the primary tumor in 85% of cases and in 15% on recurrent tumors
hence; MMR status analysis was performed after a first line of concomitant temozolomide and radiation
therapy. MGMT proved methylated in 161/300 patients (53.7%) and IDH (isocitrate dehydrogenase)
was of wild-type in 267/315 (84.4%). IHC (Immunohistochemistry) analysis of PD-L1 expression was
performed in 150 samples, with no expression of PD-L1 in 66% of them and PD-L1 expression >0% in
34% of them.
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Table 1. Patient characteristics.
All Patients Patients with Grade III Patients with Grade IV
No. of patients 355 40 315
Age at diagnosis, years a 56 (45–65) 35 (31–46) 58 (48–66)
Females 114 (32.1) 14 (35.0) 100 (31.7)
Males 241 (67.9) 26 (65.0) 215 (68.3)
Grade: b 40 (11.3) 315 (88.7)
PS:
0 190 (53.5) 22 (55.0) 168 (53.3)
1 120 (33.8) 13 (32.5) 107 (34.0)
2 39 (11.0) 5 (12.5) 34 (10.8)
3 6 (1.7) 0 (0.0) 6 (1.9)
Surgery
Non-radical 105 (29.6) 10 (25.0) 95 (30.2)
Radical 250 (70.4) 30 (75.0) 220 (69.8)
Analyzed tissue:
Diagnosis 301 (84.8) 30 (75.0) 271 (86.0)
Recurrence 54 (15.2) 10 (25.0) 44 (14.0)
MGMT status: c
Unmethylated 139 (46.3) 2 (9.1) 137 (493)
Methylated 161 (53.7) 20 (90.9) 1412 (50.7)
IDH status: d
Wild type 267 (84.8) 9 (29.2) 258 (91.2)
Mutated 48 (15.2) 23 (71.8) 25 (8.8)
PD-L1 expression: e
0% 99 (66.0) 19 (100.0) 80 (61.1)
>0% 51 (34.0) 0 (0.0) 51 (38.9)
MMR protein expression:
Retained 312 (87.9) 27 (67.5) 285 (90.5)
Partial loss 28 (7.9) 9 (22.5) 19 (6.0)
Complete loss 15 (4.2) 4 (10.0) 11 (3.5)
Data expressed as n (%) or a median (IQR). b Grade III included 31 anaplastic astrocytoma, 2 Anaplastic ependymoma,
1 anaplastic ganglioneuronal tumor, and 6 anaplastic oligodendroglioma, while all grade IV were glioblastoma.
Data not available in c 55, d 40, and e 205 patients.
2.2. Mismatch Repair Status
IHC analysis identified immunohistochemical loss of MMR protein expression (partial or complete)
in 43/355 (12.1%) patients; among these, 15/355 showed a complete immunohistochemical loss of at
least one MMR protein (4.2%). Both MSH2 and MSH6 were proven lost in 14/43 (33%) patients (11/43
and 3/43 with partial and complete loss, respectively), while both PMS2 and MLH1 were lost in 10/43
(23%) patients (5/43 with partial loss and 5/43 with complete loss). Partial or complete loss of at least
one MMR protein was found in 13/40 (32.5%) grade III patients and 30/315 (9.5%) grade IV patients.
Mismatch repair status is summarized in Figure 1.
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recurrence (p = 0.002) or after chemotherapy (p = 0.03), and in patients with mutated IDH (p = 0.0005). 
No statistically significant association was found between immunohistochemical loss of MMR 
protein expression and sex (p = 0.81), radiotherapy before tissue analysis (p = 0.23), MGMT 
methylation status (p = 0.30), and PD-L1 expression (p = 0.15). In patients with immunohistochemical 
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received before the analysis, as well as disease recurrence (p = 0.02) (Supplementary Materials Figure 
S2). Sub-analysis stratified by grade III/IV is reported in Table 2. The association between 
immunohistochemical loss of MMR proteins and tissue samples obtained at recurrence was 
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statistical significance. The small number of grade III patients did not allow us to identify any 
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Figure 1. Characterist cs of im unohistochemical expression of M R (Mismatch Repair) proteins in
our cases.
2.3. Mismatch Repair Deficiency and Clinical/Molecular Characteristics
The association between immunohistochemical loss of MMR protein expression and
clinical/molecular characteristics is shown in Figure 2 (numerical data in Table 2). This molecular
alteration was more frequent in grade III vs. IV gliomas (p < 0.0001), in tissue samples obtained at
recurrence (p = 0.002) or after chemotherapy (p = 0.03), and in patients with mutated IDH (p = 0.0005).
No statistically significant association was found between immunohistochemical loss of MMR protein
expression and sex (p = 0.81), radiotherapy before tissue analysis (p = 0.23), MGMT methylation status
(p = 0.30), and PD-L1 expression (p = 0.15). In patients with immunohistochemical complete loss of
MMR protein expression (15/355), there was a statistically significant correlation between the presence
of this alteration and the chemotherapy (p = 0.002) and radiotherapy (p = 0.02) received before the
analysis, as well as disease recurrence (p = 0.02) (Supplementary Materials Figure S2). Sub-analysis
stratified by grade III/IV is reported in Table 2. The association between immunohistochemical loss
of MMR proteins and tissue samples obtained at recurrence was confirmed (p = 0.003) in grade IV
patients, while the other associations showed a trend towards statistical significance. The small number
of grade III patients did not allow us to identify any statistically significant association.
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Figure 2. Association between immunohistochemical loss of MMR protein expression and clinical/
molecular characteristics.
2.4. Loss of Mismatch Repair Proteins and Survival
Median follow-up was 16 months (IQR 16–20). Two-year OS was 42% in the study cohort (82% in
grade III patients and 36% in grade IV patients). Median OS was 20 months (95% CI 18 to 23 months),
by grade: 94 months (95% CI 76 to NA months) in grade III patients and 18 months (95% CI 17
to 21 months) in grade IV patients. Two-year PFS was 19% in the study cohort (53% in grade III
patients and 14% in grade IV patients). Median PFS was 10 months (95% CI 9 to 11 months), by grade:
26 months (95% CI, 20 to 45 months) in grade III patients and 9 months (95% CI 9 to 10 months)
in grade IV patients. OS and PFS data are shown in Figure 3. At multivariable analysis (Table 3),
immunohistochemical loss of MMR proteins expression was not associated with PFS (HR 1.05; 95% CI
0.55 to 2.01; p = 0.89) or OS (HR 0.72; 95% CI 0.28 to 1.86; p = 0.50). Impaired PFS was associated with
wild-type IDH (HR 4.73, 95% CI 1.54 to 14.48; p = 0.007), while impaired OS was associated with poor
performance status (HR 4.87, 95% CI 1.86 to 12.79; p = 0.001) and unmethylated MGMT (HR 2.03,
95% CI 1.01 to 4.08; p = 0.04).
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Table 2. Association between immunohistochemical loss of MMR protein expression and clinical/molecular characteristics.

































Males 28/241 (11.6) 16:12 6/26 (23.1) 3:3 22/215 (10.2) 13:9
Grade:
<0.0001 - - - - - -III 13/40 (32.5) 9:4
IV 30/315 (9.5) 19.11
Analyzed
tissue at:
0.002 0.70 0.003Diagnosis 29/301 (9.6) 20:9 9/30 (30.0) 7:2 20/271 (7.4) 13:7
Recurrence 14/54 (25.9) 8:6 4/10 (40.0) 2.2 10/44 (22.7) 6:4
RT before
tissue
analysis: 0.23 0.99 0.25
No 33/299 (11.0) 24:9 10/30 (33.3) 9:1 23/269 (8.6) 15:8
Yes 10/56 (17.9) 4:6 3/10 (30.0) 0:3 7/46 (15.2) 4:3
CT before
tissue
analysis: 0.03 0.70 0.08
No 31/300 (10.3) 23:8 9/30 (30.0) 8:1 22/270 (8.1) 15:7
Yes 12/55 (21.8) 5:7 4/10 (40.0) 1:3 8/45 (17.8) 4.4
MGMT status:
0.30 0.99 0.90Unmethylated 12/139 (8.6) 5:7 0/2 (0.0) 0:0 12/137 (8.8) 5:7
Methylated 21/161 (13.0) 15:6 7/20 (35.0) 5.2 14/141 (9.9) 10:4
IDH status:
0.0005 0.99 0.09Wild type 23/267 (8.6) 13:10 3/9 (33.3) 2.1 20/258 (7.8) 11:9
Mutated 13/48 (27.1) 8:5 8/23 (34.8) 5:3 5/25 (20.0) 3:2
PD-L1
expression:
0.15 NA 0.770% 18/99 (18.2) 12:6 9/19 (47.7) 7:2 9/80 (11.3) 5:4
>0% 4/51 (7.8) 3.1 0/0 2:2 4/51 (7.8) 3:1
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Table 3. Multivariable analysis of progression-free survival and overall survival.
Progression-Free Survival Overall Survival
Hazard Ratio (95% CI) p-Value Hazard Ratio (95% CI) p-Value
Immunohistochemical
loss of MMR
protein expression: 0.89 0.50
No Reference Reference
Yes 1.05 (0.55 to 2.01) 0.72 (0.28 to 1.86)
Age, years 1.00 (0.98 to 1.02) 0.71 1.01 (0.98 to 1.03) 0.58
Grade:
0.22 0.09III Reference Reference
IV 2.09 (0.64 to 6.79) 4.95 (0.76 to 32.22)
Surgery:
0.10 0.48Radical Reference Reference
Non-radical 1.66 (0.90 to 3.05) 1.34 (0.59 to 3.05)
PS:
0 Reference Reference
1 1.38 (0.82 to 2.31) 0.22 1.83 (0.85 to 3.92) 0.12
2–3 1.61 (0.85 to 3.05) 0.15 4.87 (1.86 to 12.79) 0.001
MGMT status:
0.14 0.04Unmethylated 1.41 (0.90 to 2.23) 2.03 (1.01 to 4.08)
Methylated Reference Reference
IDH status:
0.007 0.23Wild type 4.73 (1.54 to 14.48) 2.99 (0.51 to 17.51)
Mutated Reference Reference
2.5. Survival in Patients with Immunohistochemical Loss of MMR Proteins Expression
The 43 patients with immunohistochemical loss of MMR protein expression were divided into
15 and 28 patients with complete or partial loss of at least one MMR protein expression, respectively.
No statistically significant difference between the two groups in terms of PFS and OS was demonstrated.
Median PFS was 15 months (95% CI 9–24) in patients with complete loss of MMR protein expression
and 12 months (95% CI 10–26) for those with partial loss expression. Median OS was 19 months
(95% CI 16-NA) in patients with complete loss of MMR protein expression and 76 months (95% CI
19-NA) for those with partial loss of MMR protein expression. Survival curves stratified by complete
and partial MMR expression are reported in Figure 4.




Figure 4. Progression-free survival and overall survival in patients with complete (n = 15) and partial 
(n = 28) loss of MMR protein expression. 
3. Discussion 
In this retrospective and multicenter study, we identified a small group of high-grade glioma 
patients, with immunohistochemical loss of mismatch repair protein expression: 12% of screened 
patients reported a “partial” or “total” loss of expression of one or more MMR complex proteins 
(MSH2, MSH6, MLH1, and PMS2). We found a higher probability of immunohistochemical loss of 
MMR proteins in grade III than in grade IV gliomas, at recurrence, in patients receiving 
temozolomide therapy and in IDH-mut gliomas. In patients with immunohistochemical complete 
loss of MMR protein expression, a statistically significant correlation between the presence of this 
alteration and the chemotherapy and radiotherapy received before the analysis, as well as disease 
recurrence, was found. As already reported in the literature [19], grade III gliomas are different 
entities compared to grade IV tumors from several viewpoints; in our population, 72% of grade III 
tumors reported an IDH mutation compared to only 8% in glioblastoma patients. In particular, the 
presence of mutated IDH can affect epigenetic alterations and lead to a higher probability of 
alteration of MMR protein expression in grade 3 gliomas. Moreover, immunohistochemical loss of 
MMR protein expression may be useful to detect hypermutated cancers as demonstrated by McCord 
et al. [6]; in this study, the authors showed that IHC loss of MMR proteins can detect hypermutated 
gliomas with high sensitivity and specificity; yet, in this study, 9 out of 100 gliomas were 
hypermutated and 8 out of 9 had complete loss of expression of at least one MMR protein. All 
hypermutated patients had previously received temozolomide. Even the tumor microenvironment 
can prove different between grade 2 and grade 3 gliomas; Pinton et al. [20] showed that in the 
glioblastoma microenvironment, there are more macrophages with immunosuppressive activity 
compared to grade II–III gliomas mostly consisting of microglia with a limited or absent 
immunosuppressive activity. Knowledge of the predictors of immunotherapy efficacy is extremely 
important to identify the subgroup of patients responding to this treatment; hence, the 
immunohistochemical loss of MMR protein expression could be a valid predictor of checkpoint 
inhibitor efficacy in gliomas. Noteworthy, a large prospective study should be performed in order to 
validate this biomarker and the role of partial and total immunohistochemical loss of MMR protein 
expression. In our study, in 55 cases (15%), IHC analysis was performed on tissue obtained after 
temozolomide; in these patients, we showed a higher probability of immunohistochemical loss of 
MMR protein expression compared to the cases analyzed before temozolomide therapy. As described 
in the literature, temozolomide and other alkylating agents can cause alterations in different genes 
with consequent acquisition of a hypermutated phenotype that can also determine temozolomide 
resistance. In fact, alkylating agents can alter MMR protein expression and lead to hypermutated 
genome, with a mechanism independent from microsatellite instability [17]. The specific mechanism 
r
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3. Discussion
In this retrospective and multicenter study, we identified a small group of high-grade glioma
patients, with immunohistochemical loss of mismatch repair protein expression: 12% of screened
patients reported a “partial” or “total” loss of expression of one or more MMR complex proteins
(MSH2, MSH6, MLH1, and PMS2). We found a higher probability of immunohistochemical loss of
MMR proteins in grade III than in grade IV gliomas, at recurrence, in patients receiving temozolomide
therapy and in IDH-mut gliomas. In patients with immunohistochemical complete loss of MMR
protein expression, a statistically significant correlation between the presence of this alteration and the
chemotherapy and radiotherapy received before the analysis, as well as disease recurrence, was found.
As already reported in the literature [19], grade III gliomas are different entities compared to grade
IV tumors from several viewpoints; in our population, 72% of grade III tumors reported an IDH
mutation compared to only 8% in glioblastoma patients. In particular, the presence of mutated
IDH can affect epigenetic alterations and lead to a higher probability of alteration of MMR protein
expression in grade 3 gliomas. Moreover, immunohistochemical loss of MMR protein expression
may be useful to detect hypermutated cancers as demonstrated by McCord et al. [6]; in this study,
the authors showed that IHC loss of MMR proteins can detect hypermutated gliomas with high
sensitivity and specificity; yet, in this study, 9 out of 100 gliomas were hypermutated and 8 out of 9 had
complete loss of expression of at least one MMR protein. All hypermutated patients had previously
received temozolomide. Even the tumor microenvironment can prove different between grade 2 and
grade 3 gliomas; Pinton et al. [20] showed that in the glioblastoma microenvironment, there are more
macrophages with immunosuppressive activity compared to grade II–III gliomas mostly consisting
of microglia with a limited or absent immunosuppressive activity. Knowledge of the predictors of
immunotherapy efficacy is extremely important to identify the subgroup of patients responding to this
treatment; hence, the immunohistochemical loss of MMR protein expression could be a valid predictor
of checkpoint inhibitor efficacy in gliomas. Noteworthy, a large prospective study should be performed
in order to validate this biomarker and the role of partial and total immunohistochemical loss of MMR
protein expression. In our study, in 55 cases (15%), IHC analysis was performed on tissue obtained
after temozolomide; in these patients, we showed a higher probability of immunohistochemical loss of
MMR protein expression compared to the cases analyzed before temozolomide therapy. As described
in the literature, temozolomide and other alkylating agents can cause alterations in different genes
with consequent acquisition of a hypermutated phenotype that can also determine temozolomide
resistance. In fact, alkylating agents can alter MMR protein expression and lead to hypermutated
genome, with a mechanism independent from microsatellite instability [17]. The specific mechanism
that determines this phenomenon is still unclear but it is hypothesized that temozolomide may exert
a selective pressure on tumor clones specifically targeting for MMR loss (in particular, MSH6) and
that some post-translational changes in the subcellular localization of MMR heterodimers, in response
to the alkylating action, may be partly responsible for loss of MMR proteins expression [17]. Indeed,
we performed an MSI analysis (assessed using the Titano Kit, Diatech Pharmacogenetics, that analyzes
six poly-A microsatellite BAT25, BAT26, BAT40, NR21, NR24, and TGFβRII and four dinucleotide
markers D2S123, D17S250, D5S346, and D18S58) on a small group of patients (12/355), and none
showed the presence of microsatellite instability. To date, it is unclear whether hypermutations induced
by temozolomide treatment are immunogenic or not; moreover, we recorded a deficit of expression of
one or more MMR proteins in 31 patients (9%), in which IHC analysis were performed on primary
diagnosis and microsatellite was stable; these cases remain unclear and, likely, the loss of MMR
protein expression can be independent of microsatellite status, as already reported in other papers [4].
The correlation shown in our study between immunohistochemical loss of MMR protein expression
and recurrent gliomas is in line with previous papers demonstrating a different expression profile of
MMR proteins between diagnosis and recurrence disease. Indeed, Felsberg et al. [21], comparing the
expression of MSH2, MSH6, MLH1, and PMS2 in primary and recurrent glioblastoma, demonstrated a
significantly lower MSH2, MSH6, and PMS2 expression in recurrent GBM. Nevertheless, Cahill and
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colleagues [17] detected MSH6 mutations in 3 of 14 recurrent brain tumors, but no mutation of MSH6
in 40 pretreatment GBM, suggesting that loss of MSH6 expression might set in during temozolomide
treatment. Another work showed that MLH1 expression was significantly reduced at recurrence
compared to the original tumor [16].
In summary, we identified, in this study, a population of patients with high-grade glioma with
a higher probability of loss of MMR protein expression. This molecular alteration seems to be more
present in grade III gliomas (p < 0.0001), in the tissue analyzed at relapse (p = 0.002), and after receiving
chemotherapy (p = 0.03) as well as in IDH-mut patients (p = 0.0005). These data could allow us to
identify patients who could benefit from immune checkpoint inhibitors treatment. In a recent work,
Lombardi et al. [22], demonstrated, in a small cohort of patients with relapsed glioblastoma, that loss
of MMR protein expression cannot be considered a predictor of response to pembrolizumab [23].
These data should be confirmed, also in light of the analyses performed by our study, in a larger
population and after careful selection of patients.
4. Materials and Methods
4.1. Study Design
This is a multicenter and retrospective study evaluating MMR status in all consecutive patients
treated for grade III–IV glioma between April 2018 and May 2019. The study was approved by the local
ethics committee (number 8/2019) and complied with International Ethical Guidelines for Biomedical
Research Involving Human Subjects, good clinical practice guidelines, and the Declaration of Helsinki.
The participating centers were the Veneto Institute of Oncology (Padua), the Humanitas Cancer Center
(Rozzano, Milan), and the Santa Maria della Misericordia University Hospital (Udine).
4.2. Patients
All consecutive patients treated for grade III–IV glioma at the participating centers between
April 2018 and May 2019 were evaluated for inclusion. Inclusion criteria were at least 18 years of
age, histologically confirmed diagnosis of grade III or IV glioma, and tumor tissue available for
immunohistochemical analysis resulting from the first or subsequent surgery.
4.3. Procedures
After obtaining written informed consent for each patient, we retrospectively collected and
analyzed the tumor tissue with high-grade glioma diagnosis (grade III and IV according to 2017 WHO
Classification of Central Nervous System Tumors), undergoing one or more neurosurgical interventions
and treated at the participating centers. We evaluated the expression of four major proteins of the
MMR complex (MSH2, MHH6, MLH1, and PMS2) and defined immunohistochemical loss of MMR
proteins as partial or complete loss of the expression of one or more MMR proteins.
The mismatch repair status was determined by examining the loss of protein expression by
immunohistochemistry of four MMR enzymes (MLH1, PMS2, MSH2, and MSH6; Dako, Glostrup,
Denmark); expressions of these four proteins were considered “present” (+/+) in the case of unequivocal
nuclear labeling in tumor cells with staining intensity comparable to that of internal control, “partial loss”
(+/−) in the case of visible nuclear labeling in tumor cells, but with an intensity weaker than the
internal control or only comparable to the intensity of the inert stromal cells, and “complete loss”
(−/−) in the case of no visible nuclear labeling in tumor cells. MGMT promoter methylation status
was analyzed by pyrosequencing technology using a commercially available kit (MGMT plus®,
Diatech Pharmacogenetics, Jesi, Italy) according to manufacturer’s instructions on a PyroMark TM
Q96 ID system (Qiagen, Hilden, Germany) with PyroMark CpG (Qiagen) software.
Immunohistochemistry with anti-PD-L1 primary antibodies was performed using the BOND-MAX
system (Leica Biosystems). Immunostainings were jointly assessed by two pathologists.
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4.4. Data Collection
Clinical, histological, and molecular characteristics of included patients were collected. Information
about the time of surgery and the type of chemotherapy and/or radiotherapy treatment was also
collected. Progression-free survival was calculated from the date of diagnosis to the date of the last
follow-up visit or the date of radiological progression according to RANO (Response Assessment in
Neuro-Oncology) criteria. Overall survival was calculated from the date of diagnosis to the date of the
last follow-up visit or the date of the death.
4.5. Statistical Analysis
Data were presented as median with interquartile range (IQR) or absolute frequency with
percentage (%). The association between immunohistochemical loss of MMR proteins and
clinical/molecular characteristics was evaluated using the Chi-square test and Fisher’s exact test.
Survival curves were estimated with the Kaplan–Meier method and compared using a log-rank
test. Median survival (with 95% confidence interval) was also calculated. The upper-bound of
the confidence interval for overall survival could not be calculated in some subgroups and was
indicated as “not available” (NA). Cox regression models were estimated to evaluate the effect of
immunohistochemical loss of MMR proteins expression on overall survival (OS) and progression-free
survival (PFS), adjusting for clinically relevant confounders. Effect sizes were expressed as hazard
ratio (HR) with 95% confidence interval (CI). All tests were 2-sided and a p-value less than 0.05
was considered statistically significant. Data analysis was performed using R 4.0 (R Foundation for
Statistical Computing, Vienna, Austria) [23].
5. Conclusions
In conclusion, we identified a specific subgroup of high-grade glioma patients with
immunohistochemical loss of MMR protein expression. We showed no correlation between MMR
protein expression status and survival. However, this characteristic could be a valid biomarker of
checkpoint inhibitor efficacy, but a larger study is needed to analyze and confirm this hypothesis.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/18/6716/s1,
Supplementary Figure S1. Association between immunohistochemical PARTIAL LOSS of MMR protein expression
and clinical/molecular characteristics. Supplementary Figure S2. Association between immunohistochemical
COMPLETE LOSS of MMR protein expression and clinical / molecular characteristics
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